On 3 September 2024, Bloomberg reported that Sandoz is planning a 2026 biosimilar semaglutide launch in Canada, reportedly after Novo Nordisk’s patent protection expires. Sandoz launches in the US and Europe are not planned until the early 2030s.
This comes after Biocon’s announcement in April 2024 that it entered an exclusive licensing and supply agreement with Biomm for generic Ozempic® (semaglutide) in Brazil. In the same month, Hangzhou Jiuyan Gene Engineering’s application for generic Ozempic® was accepted by regulators in China.